Abemaciclib
Breast Fibrocystic Change
Mayo ClinicSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Breast Fibrocystic Change cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
TAMOXIFEN Medical College and Hospital Kolkata | Phase 4 | BB |
Xiaoyao Pill First Affiliated Hospital Xi'an Jiaotong University | Phase 4 | BB |
Xiaoru Sanjie Capsules First Affiliated Hospital Xi'an Jiaotong University | Phase 4 | BB |
Iodine Symbollon Pharmaceuticals | Phase 3 | B |
Danazol FemmePharma Global Healthcare, Inc. | Phase 2 | B |
Same molecule, other indications
Abemaciclib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →